Key result
Drug therapy problems were identified in 68.8% of ambulatory heart failure patients, with an average of 2.51 problems per patient, most commonly involving drug interactions and noncompliance.
Why the study?
Drug therapy problems contribute to negative clinical outcomes and worsen prognosis in heart failure, motivating an assessment of these problems, associated factors, and patient satisfaction.
Cross-Sectional (n=423)
No
Answers are grounded in this paper and cite their sources.
There is a high prevalence of drug therapy problems (68.8%), particularly drug interactions and noncompliance, among ambulatory heart failure patients in Ethiopia, highlighting the need for closer medication monitoring.
BACKGROUND: Drug therapy problems (DTPs) are major concerns of healthcare and have been identified to contribute to negative clinical outcomes. The occurrence of DTPs in heart failure patients is associated with worsening of outcomes. The aim of this study was to assess DTPs, associated factors and patient satisfaction among ambulatory heart failure patients at Tikur Anbessa Specialized Hospital (TASH). METHODS: A hospital based prospective cross-sectional study was conducted on 423 heart failure patients on follow up at TASH. Data was collected through patient interview and chart review. Descriptive statistics, binary and multiple logistic regressions were used for analyses and P < 0.05 was used to declare association. RESULTS: Majority of the patients were in NYHA class III (55.6%) and 66% of them had preserved systolic function. DTPs were identified in 291(68.8%) patients, with an average number of 2.51±1.07.per patient. The most common DTPs were drug interaction (27.3%) followed by noncompliance (26.2%), and ineffective drug use (13.7%). β blockers were the most frequent drug class involved in DTPs followed by angiotensin converting enzyme inhibitors. The global satisfaction was 78% and the overall mean score of treatment satisfaction was 60.5% (SD, 10.5). CONCLUSION: Prevalence of DTPs as well as non-adherence among heart failure patients on follow up is relatively high. Detection and prevention of DTPs along with identifying patients at risk can save lives, help to adopt efficient strategies to closely monitor patients at risk, enhance patient's quality of life and optimize healthcare costs.
No takes yet. Share an insight, caveat, or question.
Seid et al. (2020) conducted a cross-sectional in heart failure (n=423). Drug therapy problems was evaluated on Prevalence of drug therapy problems. Drug therapy problems were identified in 68.8% of ambulatory heart failure patients, with an average of 2.51 problems per patient, most commonly involving drug interactions and noncompliance.
Synapse has enriched 10 related papers. Consider them for comparative context: